Black checkmark with a sparkle and a curved line underneath on a white background.
Company

United Health Products, Inc.

Ticker
UEEC
Sector
Industry
Report date
November 17, 2026
Valye AI Score

94

Very high visibility
Recent developments
Recent developments summary

Recent news includes updates on the company’s PMA application and broader healthcare sector developments.

Recent developments:
  • United Health Products provided an update on its FDA Premarket Approval application process for CelluSTAT hemostatic gauze [N9].
  • The company continues to address FDA requests and regulatory challenges related to its clinical studies and PMA application [S1][S2].
  • The company is exploring strategic alternatives including partnerships and potential sale to industry participants [S1].
Overview

United Health Products, Inc. specializes in a patented hemostatic gauze product, CelluSTAT, designed to control bleeding in healthcare settings. The product is FDA 510(k) cleared for superficial bleeding but is undergoing regulatory review for Class III surgical applications in the U.S. and Europe. The company has faced regulatory challenges including FDA Warning Letters related to clinical study compliance and is actively addressing these through corrective actions and proposed supplemental studies. Manufacturing is outsourced to FDA-certified suppliers in the U.S. The company operates in a competitive wound care market dominated by large established firms. Financially, the company has no reported revenue and significant operating losses, with liquidity constraints and convertible debt maturing at the end of 2026. Strategic alternatives including partnerships and potential sale are under consideration.

Executive summary

United Health Products, Inc. develops and markets CelluSTAT, a patented hemostatic gauze for wound care, currently approved for superficial bleeding but seeking FDA Premarket Approval for Class III surgical use. The company has disclosed detailed regulatory interactions including FDA feedback and corrective actions related to clinical studies. Financially, as of September 30, 2026, the company reported no revenue, a net loss of $185,268, and liquidity challenges with a current ratio of 0.01. The company is exploring strategic alternatives including partnerships and potential sale. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.

Scenarios for UEEC

Bull case model:

The company’s CelluSTAT gauze has demonstrated safety and efficacy in clinical trials and holds FDA 510(k) clearance for superficial bleeding. Achieving FDA Premarket Approval for Class III surgical use could open access to a premium market segment with fewer competitors. Strategic partnerships or a sale to an established industry player could accelerate commercialization and revenue growth. The company’s patented technology and ongoing regulatory engagement support potential market entry in specialized surgical applications.

Bear case model:

The company faces significant regulatory hurdles, including FDA Warning Letters and requests for additional clinical data, which delay or may prevent approval for Class III surgical use. The company has no current revenue and limited liquidity, with substantial convertible debt maturing soon and insufficient authorized shares to cover conversions. Failure to secure financing or partnerships could impair operations or lead to insolvency. Competition from large, well-funded companies and uncertain regulatory outcomes pose material risks to business viability.

Moat:

United Health Products holds patents protecting its hemostatic gauze technology through 2029 and has FDA 510(k) clearance for superficial bleeding applications. The company is pursuing FDA Premarket Approval for Class III surgical markets, which have fewer competitors and higher barriers to entry. However, the company faces competition from large established medical device companies with greater resources. The regulatory approval process and intellectual property provide some barriers, but the company’s limited scale and financial constraints reduce its competitive moat.

Risks overview
Risks summary
The most significant risks relate to regulatory approval uncertainty and financial liquidity constraints, which together could materially impact the company’s ability to execute its business strategy.
Risks details:

• Regulatory Approval Risk: The company’s business strategy depends on obtaining FDA Premarket Approval for Class III surgical use of CelluSTAT. FDA has issued Warning Letters citing clinical study violations and requested additional data, creating uncertainty around approval timing and outcome.
• Financial and Liquidity Risk: As of September 30, 2026, the company has very limited cash and current assets relative to current liabilities, resulting in a very low current ratio. Convertible notes totaling over $500,000 mature at year-end 2026, and the company lacks funds to repay them, requiring refinancing or conversion.
• Capital Structure Risk: The company has insufficient authorized shares to cover all potential conversions of outstanding convertible notes, warrants, and restricted stock units, which could lead to defaults or limit capital raising ability.
• Competitive Risk: The wound care market is dominated by large, established companies with greater resources. The company’s limited scale and financial constraints may hinder its ability to compete effectively.
• Execution Risk: The company’s plans to commercialize CelluSTAT depend on successful regulatory approval, strategic partnerships, or sale transactions, none of which are assured.

FINAL FORECAST FOR UEEC

Final take one line
United Health Products has a clear regulatory-driven business model with significant financial and execution risks related to FDA approval and liquidity constraints.
Final take 12 to 24 month view

Business trends: The company is focused on obtaining FDA Premarket Approval for its CelluSTAT gauze to enter the Class III surgical market and is exploring strategic partnerships or sale opportunities.
Execution milestones: Key milestones include resolving FDA Warning Letters, completing supplemental clinical studies, conducting a Good Clinical Practices audit, and securing financing or partnerships.
Key risks: Regulatory approval uncertainty, limited liquidity and capital structure constraints, competitive pressures, and execution risks related to commercialization and financing.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

94
LLM visibility overview
LLM Visibility known facts
  • United Health Products, Inc. develops, manufactures, and markets a patented hemostatic gauze called CelluSTAT for healthcare and wound care sectors [S1].
  • CelluSTAT is derived from cotton, designed to absorb exudate and control bleeding from superficial wounds [S1].
  • The company is seeking FDA Premarket Approval (PMA) for CelluSTAT to sell into U.S. Class III and European CE Mark human surgical markets [S1].
  • CelluSTAT has FDA 510(k) approval since 2012 for superficial bleeding use but not yet for Class III surgical use [S1].
  • The company submitted a full PMA application in March 2024 and has received FDA feedback including a Deficiencies Letter and a Warning Letter related to clinical study violations [S1].
  • The FDA requested additional clinical data and the company is addressing these requests, including proposing supplemental studies and corrective actions [S1].
  • The company is engaged in discussions with the FDA and potential corporate partners for collaboration on further clinical studies and commercialization [S1].
  • United Health Products has a contract manufacturing arrangement with an FDA-certified supplier for its gauze products, which are cut, packaged, and sterilized in the U.S. [S1].
  • The company holds patents protecting its hemostatic gauze technology through 2029 and has registered trademarks for several product formats [S1].
  • The wound care market is competitive with large established companies such as Baxter, Becton Dickinson, Johnson & Johnson, Teleflex, and 3M [S1].
  • The company has a history of operating losses, with net losses of $2,669,348 in 2025 and $2,001,733 in 2024 [S1].
  • As of September 30, 2026, the company reported cash and equivalents of $31,955 and current assets of $27,382, but current liabilities of $4,271,427, resulting in a current ratio of 0.01 and cash ratio of 0.01 [S2].
  • The company had zero revenue and a net loss of $185,268 for the period ending September 30, 2026 [S2].
  • The company faces risks related to insufficient authorized shares to cover convertible notes and warrants, which mature December 31, 2026, and it lacks funds to repay these notes, requiring refinancing or conversion [S2].
  • The company is considering strategic alternatives including partnerships, sale, merger, or licensing agreements to commercialize its products [S1].
  • Recent news items mention United Health Products providing updates on its PMA application and regulatory/legal developments in the healthcare sector [N1][N2][N3][N4][N5][N6][N7][N8].
Sources
Sources - Context summary

Generated 2026-11-17

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-04-15 | 10-K
  • S2 | 2026-11-17 | 10-Q
Sources - News headlines
  • N1 | 2026-11-17 | www.nasdaq.com | Corn Posting Tuesday Gains with Spillover Wheat Support | https://www.nasdaq.com/articles/corn-posting-tuesday-gains-spillover-wheat-support
  • N2 | 2026-11-17 | www.nasdaq.com | Lower French Production Boosts Sugar Prices | https://www.nasdaq.com/articles/lower-french-production-boosts-sugar-prices
  • N3 | 2026-11-17 | www.nasdaq.com | Stock Indexes Fall as Tech Stocks Retreat Ahead of Nvidia’s Earnings | https://www.nasdaq.com/articles/stock-indexes-fall-tech-stocks-retreat-ahead-nvidias-earnings
  • N4 | 2026-11-17 | www.nasdaq.com | Cotton Showing Modest Tuesday Morning Gain | https://www.nasdaq.com/articles/cotton-showing-modest-tuesday-morning-gain
  • N5 | 2026-11-17 | www.nasdaq.com | Worried About Nvidia? 3 Artificial Intelligence (AI) Stocks That May Be Safer Buys Right Now | https://www.nasdaq.com/articles/worried-about-nvidia-3-artificial-intelligence-ai-stocks-may-be-safer-buys-right-now
  • N6 | 2026-11-17 | www.nasdaq.com | Cotton Closes Monday with Losses | https://www.nasdaq.com/articles/cotton-closes-monday-losses
  • N7 | 2026-11-17 | www.nasdaq.com | Wheat Popping Higher After Ukrainian Strike | https://www.nasdaq.com/articles/wheat-popping-higher-after-ukrainian-strike
  • N8 | 2026-11-17 | www.nasdaq.com | Soaring ICE Inventories Weigh on Cocoa Prices | https://www.nasdaq.com/articles/soaring-ice-inventories-weigh-cocoa-prices-0
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine